Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
1.720
-0.060 (-3.37%)
Apr 24, 2025, 10:23 AM EDT - Market open
Company Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia.
The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders.
Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Minerva Neurosciences, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jul 1, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Remy Luthringer |
Contact Details
Address: 1500 District Avenue Burlington, Massachusetts 01803 United States | |
| Phone | 617 600 7373 |
| Website | minervaneurosciences.com |
Stock Details
| Ticker Symbol | NERV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001598646 |
| CUSIP Number | 603380205 |
| ISIN Number | US6033802058 |
| Employer ID | 26-0784194 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Remy Luthringer Ph.D. | Executive Chairman and Chief Executive Officer |
| Geoffrey Robin Race F.C.M.A., M.B.A. | President |
| Frederick W. Ahlholm CPA | Senior Vice President, Chief Financial Officer and Secretary |
| Joseph Reilly | Senior Vice President and Chief Operating Officer |
| William B. Boni | Vice President of Investor Relations and Corporate Communications |
| Prof. Michael Davidson M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2025 | 10-K/A | [Amend] Annual report |
| Mar 19, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 10-K | Annual Report |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 5, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Oct 22, 2024 | ARS | Filing |
| Oct 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 22, 2024 | DEF 14A | Other definitive proxy statements |